All In Biotech

Drug Trial Radar · NCT06970301

A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

A Single-center, Placebo-controlled, Participant-blind, Investigator-blind, Randomized, Multiple Ascending Dose in Titration Study to Assess The Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Apr 28, 2025

Primary completion

May 29, 2026

Study completion May 29, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the safety and tolerability of oral glovadalen (UCB0022) in healthy Caucasian, Japanese, and Chinese participants.

Conditions

  • Healthy Study Participants

Interventions

  • glovadalenDrug

    Study participants will receive doses of glovadalen (UCB0022) at pre-specified time points during the Treatment Period of Part A and Part B.

  • PlaceboOther

    Study participants will receive matching placebo at pre-specified time points during the Treatment Period of Part A and Part B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of TEAEs (Part A)Time frame: From Baseline to the end of Safety Follow-up Period (up to 49 days)
  2. Occurrence of TEAEs (Part B)Time frame: From Baseline to the end of Safety Follow-up Period (up to 44 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Up0135 1001

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.